Skip to content

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

  • Home
  • About US
  • Bioinsight
  • Policy Hub
  • Deals Book
  • Privacy Policy
  • Contact US

Header Toggle Sidebar

This is an example widget to show how the Header Toggle Sidebar looks by default. You can add custom widgets from the widgets in the admin.

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Fineline Cube Jan 15, 2026
Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Fineline Cube Jan 15, 2026
Company Deals

Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy

Fineline Cube Jan 15, 2026
Company Deals

WuXi Biologics Licenses Clinical‑Stage T‑Cell Engager to Zai Lab for Solid Tumor Development

Fineline Cube Jan 15, 2026
Company Deals

WuXi XDC Acquires TOT Bio in $357M Deal to Bolster ADC CDMO Leadership

Fineline Cube Jan 15, 2026
Policy / Regulatory

NHSA Releases NRDL Value Assessment Guidelines, Prioritizing 8 Drug Categories for Real‑World Evaluation

Fineline Cube Jan 15, 2026
Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Fineline Cube Jan 15, 2026
Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Fineline Cube Jan 15, 2026
Company Drug

Wuhan YZY Biopharma’s M701 Shows Promise in Phase II Study for Malignant Pleural Effusion at ESMO ASIA 2024

Fineline Cube Dec 11, 2024

China-based Wuhan YZY Biopharma Co., Ltd (HKG: 2496) has announced the presentation of results from...

Company Deals

Porton Pharma Solutions and OD Kingsley Life Sciences Form Partnership for Bio Conjugated Drug Development

Fineline Cube Dec 11, 2024

China-based Contract Development and Manufacturing Organization (CDMO) Porton Pharma Solutions (SHE: 300363) has announced a...

Company Medical Device

Stereotaxis and MicroPort EP Receive NMPA Approval for Magbot Magnetic Navigation Ablation Catheter

Fineline Cube Dec 10, 2024

US-based Stereotaxis, Inc. (NYSEAMERICAN: STXS) and its Chinese partner Shanghai MicroPort EP Medtech Co., Ltd....

Company Drug

Immunofoco’s IMC002 Earns FDA Fast-Track Designation for CLDN 18.2-Positive Gastric Cancer

Fineline Cube Dec 10, 2024

Immunofoco, a leading developer in tumor immunotherapy based in Suzhou, has announced that it has...

Company Drug

InnoVec Biotherapeutics’ IVB102 Receives FDA IND Approval for X-Linked Retinoschisis Treatment

Fineline Cube Dec 10, 2024

Beijing-based gene therapy specialist InnoVec Biotherapeutics Inc. has announced receiving Investigational New Drug (IND) approval...

Company Deals

Nona Biosciences Partners with Kodiak Sciences to Discover Multi-Target Ophthalmic Antibodies

Fineline Cube Dec 10, 2024

Nona Biosciences, a wholly-owned subsidiary of HBM Holdings Ltd (HKG: 2142), has joined forces with...

Company Drug

Eisai’s Urece (Dotinurad) Approved by China’s NMPA for Gout Treatment with Hyperuricemia

Fineline Cube Dec 10, 2024

Eisai’s (TYO: 4523) China unit has announced that it has received marketing approval from the...

Company Drug

Daiichi Sankyo and AstraZeneca’s Datopotamab Deruxtecan Earns FDA Breakthrough Therapy Designation

Fineline Cube Dec 10, 2024

Partners Daiichi Sankyo (TYO: 4568) and AstraZeneca (AZ, NASDAQ: AZN) have jointly announced that their...

Company Deals

Shanghai Pharmaceuticals and Sichuan Kelun-Biotech Partner to Expand Sacituzumab Tirumotecan Market Access

Fineline Cube Dec 10, 2024

Shanghai Pharmaceuticals (SHA: 601607; SPH) has entered into a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical...

Company Drug

China Medical System’s Methylthioninium Tablets Receive First Prescriptions for Colonoscopy Use

Fineline Cube Dec 10, 2024

China Medical System Holdings (CMS; HKG: 0867) has announced that the first prescriptions have been...

Company Drug

Dizal Pharmaceutical Unveils Promising Data on DZD8586 for B-NHL at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Dizal Pharmaceutical Co., Ltd (SHA: 688192) has presented new data from a pooled safety...

Company Drug

AbbVie’s Tavapadon Shows Positive Results in Phase III TEMPO-2 Study for Parkinson’s Disease

Fineline Cube Dec 10, 2024

US-based pharmaceutical company AbbVie (NYSE: ABBV) has revealed positive top-line results from the pivotal Phase...

Company Drug

Eli Lilly’s Jaypirca Demonstrates Superiority in BRUIN CLL-321 Study for CLL/SLL Treatment

Fineline Cube Dec 10, 2024

US pharmaceutical major Eli Lilly and Company (NYSE: LLY) unveiled the latest data from the...

Policy / Regulatory

CDE Releases 89th Batch of Reference Preparations for Generic Quality Consistency

Fineline Cube Dec 10, 2024

The Center for Drug Evaluation (CDE) in China has announced the selection of the 89th...

Company Deals

Jiangsu Hengrui Pharmaceuticals Plans Secondary Listing on Hong Kong Stock Exchange

Fineline Cube Dec 10, 2024

Jiangsu Hengrui Pharmaceuticals Co., Ltd. (SHA: 600276) has confirmed reports regarding its intention to make...

Company Drug

Keymed Biosciences Presents CM336 Data for Relapsed Multiple Myeloma at ASH Annual Meeting

Fineline Cube Dec 10, 2024

China-based Keymed Biosciences Inc., (HKG: 2162) has announced the presentation of the latest data from...

Company Drug

Antengene’s Xpovio Showcases Positive Results in Phase III BENCH and Phase I/II TOUCH Studies at ASH 2024

Fineline Cube Dec 10, 2024

China-based Antengene Corporation Limited (Antengene, HKG: 6996) announced the presentation of the latest results from...

Company Drug

Lee’s Pharmaceutical Receives NMPA Approval for Generic Glaucoma Treatments

Fineline Cube Dec 10, 2024

China-based Lee’s Pharmaceutical Holdings Ltd (HKG: 0950) subsidiary, Zhaoke Ophthalmology Ltd (HKG: 6622), has announced...

Policy / Regulatory

NMPA Proposes Draft for Simplified Registration of Traditional Chinese Medicines from Hong Kong and Macao

Fineline Cube Dec 10, 2024

The National Medical Products Administration (NMPA) has issued the “Notification on Simplifying the Registration and...

Policy / Regulatory

China’s NHSA and NHC Issue Guidelines to Enhance Volume-based Procurement Mechanism

Fineline Cube Dec 10, 2024

The National Healthcare Security Administration (NHSA) and National Health Commission (NHC) of China have released...

Posts pagination

1 … 193 194 195 … 610

Recent updates

  • Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal
  • Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%
  • Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic
  • Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination
  • Fresenius Kabi Licenses TQ Therapeutics Cell Tech for Automated T‑Cell Isolation in Cell Therapy
Special Report 2025 Q1: U.S. Targets Chinese Pharma with 200% Tariffs—Will the Global Drug Market Collapse?

Category

  • Company
  • Deals
  • Digital
  • Drug
  • General/Other
  • Hospital
  • Legal / IP
  • Medical Device
  • Others
  • Policy / Regulatory
  • R&D

You Missed

Company Deals

Bio‑Thera Solutions Licenses BAT2206 Stelara Biosimilar to Gedeon Richter in $110M Deal

Company Deals

Jiangsu Aidea Raises RMB 185 M via Private Placement to Boost Nanda Pharma Stake to 73.4%

Company Drug

Huadong Medicine’s DR10624 Wins FDA Nod for MASLD Study, First Triple Agonist to Enter Clinic

Company Drug

Ipsen’s IPN60340 Wins FDA Breakthrough Therapy Designation for First‑Line AML in Combination

Insight, China's Pharmaceutical Industry

Fineline Insights, Pharma Clarity

Copyright © 2025 | Fineline Information & Technology | BlogData by Themeansar.